Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced today that the clinical lab fee schedule (CLFS) for 2026 posted by Centers for Medicare & Medicaid Services (CMS) indicates an increase of 47%, from $1263.53 to $1853.22, for the payment for the Category I Current Procedural Terminology (CPT®) code 81195. This code applies to use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematologic malignancies, or blood cancers.

GlobeNewsWire • Dec 3, 2025

Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript

Bionano Genomics, Inc. ( BNGO ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Robert Holmlin - President, CEO, CFO & Director Conference Call Participants Kelly Gura Yi Chen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and welcome to the Bionano Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 14, 2025

Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress

SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. “Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers.

GlobeNewsWire • Nov 13, 2025

Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping (OGM) can address key limitations of targeted RNA-sequencing (RNA-seq) panels in detecting therapeutically-relevant gene rearrangements in acute leukemias. This peer-reviewed publication, entitled “Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute Leukemia,” is the first to describe the comparison of OGM and RNA-seq in cancer.

GlobeNewsWire • Nov 6, 2025

Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress.

GlobeNewsWire • Oct 30, 2025

Bionano to Participate in the H.C. Wainwright @ Home Event

SAN DIEGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will participate in the H.C. Wainwright @ Home Event on Wednesday, October 15th, 2025.

GlobeNewsWire • Oct 7, 2025

Nasdaq Surges 100 Points; Bionano Genomics Shares Plunge

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday.

Benzinga • Sep 18, 2025

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering

SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company's common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company's common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company's common stock (all the warrants, collectively, the “Series Warrants”), at a combined public offering price of $2.00 per share (or common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants have an exercise price of $2.00 per share and are immediately exercisable upon issuance. The Series E warrants will expire on the five-year anniversary of the date of issuance. The short-term Series F warrants will expire on the eighteen-month anniversary of the date of issuance.

GlobeNewsWire • Sep 17, 2025

Crude Oil Rises Over 2%; Bionano Genomics Shares Plunge

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday.

Benzinga • Sep 16, 2025

Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research.

GlobeNewsWire • Sep 16, 2025